On 9th September 2020, HTA and FutureChem signed a “Technology Co-Development Agreement”, which agrees that both sides will cooperate in the development and commercialization FC303, and HTA has the exclusive rights to develop, manufacture and sell this product in Chinese market. Founded in 1999, FutureChem is mainly engaged in the R&D and production of radiopharmaceuticals. 18F-FC303 is a 18F-labeled PSMA-specific targeted compounds that selectively accumulates in prostate cancer.
Nowadays, Prostate cancer is the second most common cancer in worldwide. Co-developed by HTA and FutureChem, FC303 has a promising application prospect on the diagnosis and treatment of prostate cancer in China. Based on this cooperation, both parties look forward to establishing a long-term strategic partnership to further cooperate in the field of radiopharmaceuticals and jointly contribute to human health.